Heart patients: which single pill works best long after stent?

NCT ID NCT02044250

Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at over 5,500 heart patients in Korea who had a drug-coated stent and took two blood thinners for about a year. After that, they were given either clopidogrel or aspirin alone for up to two more years. The goal was to see which drug better prevents heart attacks, strokes, and serious bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: clopidogrel and aspirin
What this could lead to: If it works, this could show that clopidogrel alone is safer or more effective than aspirin alone for long-term heart protection after a stent.
What could go wrong: This is a completed Phase 4 trial, so results are known. It compares two common drugs, so no major breakthrough is expected. Individual results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

5,530 people

The number who actually took part.

Started

Feb 2014

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female aged ≥20 years 2. Maintenance of dual or triple antiplatelet therapy at least 12 ± 6 months after PCI with DES 3. No history of further clinical event after PCI with DES 4. Plan to change to antiplatelet monotherapy 5. Agreement to give written informed consent Exclusion Criteria: 1. History of hypersensitivity to aspirin or clopidogrel 2. History of contraindication to aspirin or clopidogrel 3. Active pathologic bleeding, such as peptic ulcer, tumor bleeding or intracranial hemorrhage 4. History of major bleeding, BARC class ≥3, resulting in stop of antiplatelet agents within 3 months 5. Bleeding diathesis 6. Known coagulopathy or refusal of blood transfusion 7. Presence of non-cardiac comorbidity with life expectancy \<2 years from randomization 8. Plan to surgery or intervention which needs to stop antiplatelet agents ≥3 months 9. Females with childbearing potential or breast-feeding 10. Conditions that may result in protocol non-compliance by the committees 11. Co-administration of contraindicated medications as follows: other P2Y 12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral anticoagulants, or chronic therapy of heparin); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg/week); lithium 12. Refusal to give written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary heart disease

Contacts and locations

Locations

Seoul National University Hospital

Seoul, 110-744, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.